BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251014T150000
DTEND;TZID=America/Los_Angeles:20251014T160000
DTSTAMP:20260726T152336
CREATED:20250814T002133Z
LAST-MODIFIED:20250814T002133Z
UID:42597-1760454000-1760457600@solvecfs.org
SUMMARY:The Unified Platform: Advancing Research Across ME/CFS\, Long Covid\, and Other Chronic Conditions
DESCRIPTION:Chronic illnesses such as myalgic encephalomyelitis (ME) and Long COVID\, which lack clinical biomarkers\, present challenges around diagnosis\, symptom reporting\, and monitoring. That’s why the unhide® Solve Together Unified Platform–which is participant-led with continuous digital data collection–offers some advantages over traditional site-based clinical research models.  \nThe easy-to-use\, secure platform allows patients to contribute data through symptom surveys\, validated assessments\, wearable devices\, and health history to support research across 30+ related conditions. It also uncovers hidden connections between inflammation\, chronic illness\, and overall health.  \nThe Unified Platform enables patients and caregivers to: \n\nTrack symptoms and visualize health patterns over time\nConnect wearable data for more complete insights\nDownload and print customized reports to have better conversations with healthcare providers\nContribute to cross-disease research initiatives\nOptionally receive invitations to participate in clinical trials and studies\nIdentify ways to determine relationships between brain inflammation and mental health symptoms such as brain fog\, difficulty concentrating\, memory issues\, sleep problems\, mood changes\, anxiety\, and depression\n\nParticipants may contribute data across multiple domains: validated surveys (dysautonomia\, PEM\, fatigue\, function)\, daily symptom and treatment logs\, device/sensor data (Apple Watch\, Fitbit\, Garmin)\, and electronic health records (EHRs).  \nIn this webinar\, Solve CEO Emily Taylor\, Brain Inflammation Collaborative (BIC) co-founder and CEO Christy Jagdfeld\, Principal Investigator and lived experience expert Megan L. Fitzgerald\, PhD\, and platform architect and caregiver to a person with ME/CFS Chris Nowak (CareEvolution) will discuss how the unhide® Solve Together Unified Platform facilitates partnerships\, successfully improves patient-provider communication\, enables robust recruitment and multidimensional data collection\, and serves as a catalyst for better health among all who are impacted by neuroinflammation.  \nVisit unhidenow.org to learn more or enroll. \nRegister for the webinar here: https://us02web.zoom.us/webinar/register/WN_ATe5-nbxSsy89D8TcXIInw
URL:https://solvecfs.org/event/the-unified-platform-advancing-research-across-me-cfs-long-covid-and-other-chronic-conditions/
CATEGORIES:Long Covid,Research,Solve Together,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/08/UnifiedPlatformWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260115T090000
DTEND;TZID=America/Los_Angeles:20260115T100000
DTSTAMP:20260726T152336
CREATED:20251028T001815Z
LAST-MODIFIED:20251028T001815Z
UID:42923-1768467600-1768471200@solvecfs.org
SUMMARY:From Mystery to Measurable: The Science Behind the New ME/CFS Blood Test
DESCRIPTION:For the first time\, scientists have developed a simple\, accurate blood test that can potentially identify Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) — a long-term\, debilitating condition that affects millions of patients worldwide.  \nThe study (published in the Journal of Translational Medicine)\, led by the University of East Anglia in partnership with Oxford BioDynamics\, used cutting-edge 3D genomic technology to look at how DNA is folded inside blood cells. Just like origami\, the shape and folds of DNA control which genes are switched on or off.  \nThe team discovered a distinctive pattern of these folds that appears only in people with ME/CFS — providing a clear biological “fingerprint” of the disease. Using this pattern\, the researchers created a blood test that can diagnose ME/CFS with 96% accuracy. Until now\, doctors have had to rely on symptoms alone and rule out other illnesses\, a process that can take years. This test offers the potential for quicker\, more confident diagnoses and could end the uncertainty many patients face. \nBeyond diagnosis\, the findings also point toward disrupted immune and inflammation pathways\, which may help scientists develop targeted treatments in the future. The same approach could even pave the way for a similar test for Long Covid\, which shares many of the same biological features as ME/CFS. \nThis discovery marks an important turning point: it brings scientific validation to patients whose symptoms have too often been dismissed\, and it opens the door to better understanding\, earlier support\, and more effective care for people living with this complex condition. \nIn this webinar\, Solve CEO Emily Taylor will host research team members Dr. Dmitry Pshezhetskiy (University of East Anglia)\, Dr. Alexandre Akoulitchev\, MA\, PhD\, FRSM (Chief Scientific Officer\, Oxford BioDynamics)\, Bartu Ahiska (Senior Director\, Commercial Development & Marketing Comms\, Oxford BioDynamics)\, and Ewan Hunter (Chief Data and Technology Officer\, Oxford BioDynamics)\, who will discuss the development of their new blood-based assay\, the EpiSwitch CFS test\, and its potential impact on diagnosing and treating people with ME/CFS and Long Covid.
URL:https://solvecfs.org/event/from-mystery-to-measurable-the-science-behind-the-new-me-cfs-blood-test/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/10/1.15.26-From-Mystery-to-Measurable.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T083000
DTEND;TZID=America/Los_Angeles:20260416T093000
DTSTAMP:20260726T152336
CREATED:20260225T175057Z
LAST-MODIFIED:20260401T190628Z
UID:43385-1776328200-1776331800@solvecfs.org
SUMMARY:GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
DESCRIPTION:Glucagon-Like Peptide-1 (GLP-1) agonist medications\, like semaglutide\, are injectable or oral drugs that mimic the natural GLP-1 hormone\, which helps regulate insulin levels. Thus\, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion\, reducing appetite\, and increasing insulin release. \n\nBut can they also ease symptoms in people with ME/CFS and identify disease subtypes?\n\nSolve Ramsay Research Grant Program alum Dr. Carmen Scheibenbogen (acting director of the Institute for Medical Immunology of the Charité University Hospital in Berlin) recently received a Solve ME/CFS Catalyst Award for her study evaluating whether semaglutide reduces symptoms and improves quality of life for people with ME/CFS who have high BMI.\n\nIn this free educational webinar hosted by Solve Chief Scientific Officer Dr. Sadie Whittaker and VP of Scientific Programs Dr. Jessica Maya\, Dr. Scheibenbogen will discuss details of her study\, explain how her research will identify biomarkers\, and discuss how these results could help determine which patients are most likely to benefit from treatment.
URL:https://solvecfs.org/event/glp-1-drugs-to-reduce-symptoms-in-people-with-me-cfs-and-identify-disease-subgroups/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/02/ScheibenbogenMayaWhittakerTw.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260428T150000
DTEND;TZID=America/Los_Angeles:20260428T160000
DTSTAMP:20260726T152336
CREATED:20260225T175319Z
LAST-MODIFIED:20260227T012933Z
UID:43389-1777388400-1777392000@solvecfs.org
SUMMARY:The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
DESCRIPTION:Dr. Liisa Selin\, Dr. Ayano Kohlgruber\, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a person with ME/CFS and a person with Long Covid. \nThese disease-associated T cells include “exhausted” CD8+ T cells and “double-positive” CD4+/CD8+ T cells (which are found in people with autoimmune diseases\, too). The researchers hypothesize that these T cells recognize fragments of microbial proteins critical for developing the disease. The microbial protein fragments may overstimulate and exhaust the T cells. \nAlso\, fragments of human proteins may resemble these microbial protein fragments; thus\, the disease-associated T cells may cross-react with human proteins to drive an autoimmune response. \nIn this study\, the research team will screen a library of protein fragments from microbes (viruses and bacteria) that are associated with developing Long Covid or ME/CFS (e.g.\, SARS-CoV-2\, B. burgdorferi\, enteroviruses)\, and a library of protein fragments from humans (to find self-antigens). \nIf successful\, these deliverables would be important for understanding how much persisting pathogens or self-antigens can exhaust the immune system\, and how dysfunctional and exhausted immune responses contribute to ME/CFS and Long Covid. \nIn this webinar hosted by Solve M.E. VP of Scientific Programs Dr. Jessica Maya\, the panelists will discuss the study and how this work could also produce new disease biomarkers and suggest new treatments for patient subgroups\, as well as how the libraries of human leukocyte antigen–displayed microbial and human protein fragments established by this work could be valuable resources for future ME/CFS and Long Covid studies.
URL:https://solvecfs.org/event/the-discovery-of-target-antigens-for-dysfunctional-t-cells-in-me-cfs-and-long-covid/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/02/SelinSolveWebinarApril282026JMFinal-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260610T110000
DTEND;TZID=America/Los_Angeles:20260610T120000
DTSTAMP:20260726T152336
CREATED:20260512T140632Z
LAST-MODIFIED:20260512T140632Z
UID:43930-1781089200-1781092800@solvecfs.org
SUMMARY:Sequence ME & Long Covid: The Search for ME/CFS and Long Covid Biomarkers and Subtypes
DESCRIPTION:The DecodeME Project is the largest genetic study of ME/CFS conducted to date and has identified eight genetic signals where people with ME/CFS tend to differ from those without\, linked to the immune and nervous systems. These landmark findings reflect the lived experience of thousands of people with ME/CFS\, providing validation and exciting new avenues for research. \nIn earlier work\, the DecodeME team analyzed the genomes of 15\,500 people with ME/CFS\, finding critical genomic spots where variation significantly influences disease risk. Now\, with support from a Solve ME/CFS Catalyst Award\, the team will set up this ambitious project\, allowing them later to read these genomes in even more detail. \nWhile the earlier DecodeME study used technology that examined only a million genomic spots per participant\, the wider project will leverage Oxford Nanopore Technology’s new whole genome sequencing method to examine all three billion spots across the genome for most participants (9\,000 of the original 15\,500 participants). \nIn this free educational webinar\, host Dr. Jessica Maya (Solve Vice President of Scientific Programs) will talk to the DecodeME management team and recent Catalyst Award honorees Prof. Chris Ponting (Chair of Medical Bioinformatics\, University of Edinburgh)\, Sonya Chowdhury (Chief Executive\, Action For ME) and Andy Devereux-Cooke (Patient Representative and Co-Investigator at DecodeME Study) about how their study could reveal many more genes\, gene-regulation elements\, and biological pathways that affect ME/CFS risk\, advance efforts to identify new biomarkers for disease subtypes\, and ultimately lead to new treatments. \nRegister for the event here.
URL:https://solvecfs.org/event/sequence-me-long-covid-the-search-for-me-cfs-and-long-covid-biomarkers-and-subtypes/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/05/June10DecodeMEFINAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260714T150000
DTEND;TZID=America/Los_Angeles:20260714T160000
DTSTAMP:20260726T152336
CREATED:20260622T155750Z
LAST-MODIFIED:20260622T155750Z
UID:44319-1784041200-1784044800@solvecfs.org
SUMMARY:Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
DESCRIPTION:In 2025\, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study\, “Low Dose Rapamycin in ME/CFS\, Long-COVID\, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).   \nThe study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid\, repurposing rapamycin to reduce fatigue\, orthostatic intolerance\, post-exertional malaise\, and sleep issues for a subset of people with ME/CFS. \nIn this webinar hosted by Solve M.E. President Emily Taylor\, panelists Courtney Miller (Board President at Simmaron)\, Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron)\, and Dr. Avik Roy (Chief Scientific Officer at Simmaron) will discuss the latest learnings from the study\, and their plan to conduct an  NIH exploratory treatment trial based on the data. 
URL:https://solvecfs.org/event/repurposing-rapamycin-a-report-on-the-first-biomarker-driven-treatment-trial-for-me-cfs/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/06/July14SimmaronWebinar2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260812T090000
DTEND;TZID=America/Los_Angeles:20260812T100000
DTSTAMP:20260726T152336
CREATED:20260722T192831Z
LAST-MODIFIED:20260722T192831Z
UID:44685-1786525200-1786528800@solvecfs.org
SUMMARY:"Coffee With a Clinician" in Recognition of Severe M.E. Awareness Month
DESCRIPTION:Solve M.E. is proud to join our hosts from the Bateman Horne Center for a special edition of their program “Coffee with a Clinician” in observance of Severe ME/CFS Awareness Month. \nSolve President and CEO Emily Taylor\, along with representatives from Open Medicine Foundation\, #MEAction\, and the authors of What is Myalgic Encephalomyelitis Like? will share insights and updates related to Severe M.E. research and advocacy. \nDon’t miss this opportunity to hear from leaders across the ME/CFS community and learn how we can continue advancing Severe M.E. awareness\, research\, and hope. \nWednesday\, August 12 | 9:00 AM PT \n(10:00 AM MT | 11:00 AM CT | 12:00 PM ET) \nRegister for this free event here.
URL:https://solvecfs.org/event/coffee-with-a-clinician-in-recognition-of-severe-m-e-awareness-month/
CATEGORIES:Advocacy,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/07/CWC-Aug-2026-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260908T150000
DTEND;TZID=America/Los_Angeles:20260908T160000
DTSTAMP:20260726T152336
CREATED:20260512T140700Z
LAST-MODIFIED:20260512T140700Z
UID:43935-1788879600-1788883200@solvecfs.org
SUMMARY:A Safe\, Accessible Treatment for ME/CFS? The Mitochondrial Stabilizer IVO-21 Study
DESCRIPTION:As part of our commitment to advancing science that brings real hope to people living with ME/CFS or Long Covid\, Solve has selected Dr. Jay H. Chung (National Institutes of Health) as a recipient of our latest ME/CFS Catalyst Award. \nDr. Chung’s groundbreaking study\, “Mitochondrial Stabilizer IVO-21 As Therapy for ME/CFS\,” is focused on developing a new way to restore cellular energy production by targeting two of the most debilitating and poorly treated aspects of ME/CFS and Long Covid—mitochondrial dysfunction and chronic inflammation—mechanisms believed to drive symptoms such as fatigue and brain fog. \nThe compound at the heart of this study is IVO\, an inexpensive small-molecule therapy that can be easily taken as pills. Early results in cell-culture models suggest IVO restores mitochondrial energy production and reduces systemic inflammation. The next step is to evaluate how well IVO alleviates sickness behavior in preclinical (mouse) models. \nIn this free educational webinar hosted by Solve Vice President of Scientific Programs Dr. Jessica Maya\, Dr. Chung will explain why his research is an essential step toward future clinical studies that could benefit millions and how it could pave the way for a safe\, accessible treatment that addresses the root causes of these complex diseases. \nRegister here.
URL:https://solvecfs.org/event/a-safe-accessible-treatment-for-me-cfs-the-mitochondrial-stabilizer-ivo-21-study/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/05/Sept8DrChung.png
END:VEVENT
END:VCALENDAR